The figures indeed represent a broad brush over many different drug categories. Though if you were to look at neuroprotective agents, the progression from Phase 1 to market = 0%, and this includes NNZ2256's own precursor, glypromate. When one gets emotionally attached to a share, it can be difficult to distinguish between what is LIKELY to happen, and what one WISHES to happen. And you can't NEED a drug to succeed. A drug can only succeed if it is clinically useful, and if for instance a change in the incidence of non-convulsive seizures does not translate into improved patient outcomes e.g time in ICU, disability scores at 3 months, then it won't go to market. The trefoil factor antibodies may provide some further interest in the next few weeks if an announcement is forthcoming, but these are at an earlier stage than NNZ2256 and note the development time of new drugs in the article previously posted. Your positions in this company will really start paying off or not from the middle of next year in the lead up to the phase II results. If they do, I hope a significant percentage of the holders are NZers.
NEU Price at posting:
2.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)